282 related articles for article (PubMed ID: 31941474)
1. Ex vivo anti-microbial efficacy of various formaldehyde releasers against antibiotic resistant and antibiotic sensitive microorganisms involved in infectious keratitis.
Amponin DE; Przybek-Skrzypecka J; Zyablitskaya M; Takaoka A; Suh LH; Nagasaki T; Trokel SL; Paik DC
BMC Ophthalmol; 2020 Jan; 20(1):28. PubMed ID: 31941474
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial Studies Using the Therapeutic Tissue Cross-Linking Agent, Sodium Hydroxymethylglycinate: Implication for Treating Infectious Keratitis.
Rapuano PB; Scanameo AH; Amponin DE; Paulose SA; Zyablitskaya M; Takaoka A; Suh LH; Nagasaki T; Trokel SL; Paik DC
Invest Ophthalmol Vis Sci; 2018 Jan; 59(1):332-337. PubMed ID: 29346493
[TBL] [Abstract][Full Text] [Related]
3. Seasonal, geographic, and antimicrobial resistance patterns in microbial keratitis: 4-year experience in eastern Pennsylvania.
Ni N; Nam EM; Hammersmith KM; Nagra PK; Azari AA; Leiby BE; Dai Y; Cabrera FA; Ma JF; Lambert CE; Honig SE; Rapuano CJ
Cornea; 2015 Mar; 34(3):296-302. PubMed ID: 25603231
[TBL] [Abstract][Full Text] [Related]
4. Antibiotic Resistance in the Treatment of Staphylococcus aureus Keratitis: a 20-Year Review.
Chang VS; Dhaliwal DK; Raju L; Kowalski RP
Cornea; 2015 Jun; 34(6):698-703. PubMed ID: 25811722
[TBL] [Abstract][Full Text] [Related]
5. Argon Cold Plasma-A Novel Tool to Treat Therapy-resistant Corneal Infections.
Reitberger HH; Czugala M; Chow C; Mohr A; Burkovski A; Gruenert AK; Schoenebeck R; Fuchsluger TA
Am J Ophthalmol; 2018 Jun; 190():150-163. PubMed ID: 29580975
[TBL] [Abstract][Full Text] [Related]
6. Topical therapeutic corneal and scleral tissue cross-linking solutions:
Takaoka A; Cao K; Oste EM; Nagasaki T; Paik DC
Biosci Rep; 2019 May; 39(5):. PubMed ID: 30971499
[TBL] [Abstract][Full Text] [Related]
7. [Analysis of distribution and drug resistance of pathogens from the wounds of 1 310 thermal burn patients].
Zhang C; Gong YL; Luo XQ; Liu MX; Peng YZ
Zhonghua Shao Shang Za Zhi; 2018 Nov; 34(11):802-808. PubMed ID: 30481922
[No Abstract] [Full Text] [Related]
8. Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones.
Alexandrakis G; Alfonso EC; Miller D
Ophthalmology; 2000 Aug; 107(8):1497-502. PubMed ID: 10919897
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial resistance trends in bacterial keratitis over 5 years in Sydney, Australia.
Cabrera-Aguas M; Khoo P; George CRR; Lahra MM; Watson SL
Clin Exp Ophthalmol; 2020 Mar; 48(2):183-191. PubMed ID: 31671232
[TBL] [Abstract][Full Text] [Related]
10. Shifting trends in bacterial keratitis in Toronto: an 11-year review.
Lichtinger A; Yeung SN; Kim P; Amiran MD; Iovieno A; Elbaz U; Ku JY; Wolff R; Rootman DS; Slomovic AR
Ophthalmology; 2012 Sep; 119(9):1785-90. PubMed ID: 22627118
[TBL] [Abstract][Full Text] [Related]
11. Risk factors and causative organisms in microbial keratitis.
Green M; Apel A; Stapleton F
Cornea; 2008 Jan; 27(1):22-7. PubMed ID: 18245962
[TBL] [Abstract][Full Text] [Related]
12. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
[TBL] [Abstract][Full Text] [Related]
13. Characterization of virulence factors, antimicrobial resistance patterns and biofilm formation of Pseudomonas aeruginosa and Staphylococcus spp. strains isolated from corneal infection.
Heidari H; Hadadi M; Sedigh Ebrahim-Saraie H; Mirzaei A; Taji A; Hosseini SR; Motamedifar M
J Fr Ophtalmol; 2018 Nov; 41(9):823-829. PubMed ID: 30292385
[TBL] [Abstract][Full Text] [Related]
14. In vitro Evidence of Improved Antimicrobial Efficacy of Silver and Triclosan Containing Vascular Grafts Compared with Rifampicin Soaked Grafts.
Berard X; Puges M; Pinaquy JB; Cazanave C; Stecken L; Bordenave L; Pereyre S; M'Zali F
Eur J Vasc Endovasc Surg; 2019 Mar; 57(3):424-432. PubMed ID: 30301647
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial efficacy of riboflavin/UVA combination (365 nm) in vitro for bacterial and fungal isolates: a potential new treatment for infectious keratitis.
Martins SA; Combs JC; Noguera G; Camacho W; Wittmann P; Walther R; Cano M; Dick J; Behrens A
Invest Ophthalmol Vis Sci; 2008 Aug; 49(8):3402-8. PubMed ID: 18408193
[TBL] [Abstract][Full Text] [Related]
16. Trends in Microbiological and Antibiotic Sensitivity Patterns in Infectious Keratitis: 10-Year Experience in Mexico City.
Hernandez-Camarena JC; Graue-Hernandez EO; Ortiz-Casas M; Ramirez-Miranda A; Navas A; Pedro-Aguilar L; Lopez-Espinosa NL; Gaona-Juarez C; Bautista-Hernandez LA; Bautista-de Lucio VM
Cornea; 2015 Jul; 34(7):778-85. PubMed ID: 25811724
[TBL] [Abstract][Full Text] [Related]
17. In vitro antimicrobial activity of Shiva-11 against ocular pathogens.
Gunshefski L; Mannis MJ; Cullor JS; Schwab IR; Jaynes J; Smith WL; Mabry E; Murphy CJ
Cornea; 1994 May; 13(3):237-42. PubMed ID: 8033574
[TBL] [Abstract][Full Text] [Related]
18. The In Vitro Evaluation of Tigecycline and the In Vivo Evaluation of RPX-978 (0.5% Tigecycline) as an Ocular Antibiotic.
Romanowski EG; Kowalski TA; O'Connor KE; Yates KA; Mah FS; Shanks RM; Kowalski RP
J Ocul Pharmacol Ther; 2016 Mar; 32(2):119-26. PubMed ID: 26545167
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of a Fixed Combination of Tetracycline, Chloramphenicol, and Colistimethate Sodium for Treatment of Candida albicans Keratitis.
Blanco AR; Nostro A; D'Angelo V; D'Arrigo M; Mazzone MG; Marino A
Invest Ophthalmol Vis Sci; 2017 Aug; 58(10):4292-4298. PubMed ID: 28846777
[TBL] [Abstract][Full Text] [Related]
20. Keratitis antimicrobial resistance surveillance program, Sydney, Australia: 2016 Annual Report.
Watson S; Cabrera-Aguas M; Khoo P; Pratama R; Gatus BJ; Gulholm T; El-Nasser J; Lahra MM
Clin Exp Ophthalmol; 2019 Jan; 47(1):20-25. PubMed ID: 30047184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
